Axillary Lymph Node Status and neoadjuvant Therapy in HER2-positive Breast Cancer

被引：0
|
作者：
Danzinger, Autoren S. [1 ]
Pfeifer, C. [2 ]
Wimmer, S. [1 ]
Tendl-Schulz, K. [3 ]
Singer, C. F. [1 ]
机构：
[1] Med Univ Wien, Inst Univ Klin Frauenheilkunde 1, Vienna, Austria
[2] Univ Innsbruck, Inst Stat, Innsbruck, Austria
[3] Med Univ Wien, Klin Inst Pathol, Vienna, Austria
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2021年 / 81卷 / 04期
关键词：
D O I：
10.1055/s-0041-1726593
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
16
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [31] ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy
    Li, Jian-wei
    Mo, Miao
    Yu, Ke-da
    Chen, Can-ming
    Hu, Zhen
    Hou, Yi-feng
    Di, Gen-hong
    Wu, Jiong
    Shen, Zhen-zhou
    Shao, Zhi-ming
    Liu, Guang-yu
    PLOS ONE, 2014, 9 (12):
  • [32] Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation
    Takei, Hiroyuki
    Yoshida, Takashi
    Kurosumi, Masafumi
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Hayashi, Yuji
    Higuchi, Toru
    Uchida, Sayaka
    Ninomiya, Jun
    Kubo, Kazuyuki
    Oba, Hanako
    Nagai, Shigenori
    Tabei, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 547 - 553
  • [33] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [34] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [35] Discrepancy of pathologic complete response and outcome between breast tumor and axillary node in HER2-positive breast cancer after neoadjuvant chemotherapy.
    Chu, Chia-Hui
    Chen, Shin-Cheh
    Chang, Hsien-Kun
    Lin, Yung-Chang
    Shen, Shih-Che
    Kuo, Wen-Lin
    Yu, Chi-Chang
    Chou, Hsu-Huan
    Huang, Yi-Ting
    Ueng, Shir-Hwa
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 28 - 29
  • [36] Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
    Wang, Mengshen
    Wang, Mozhi
    Wang, Zhenning
    Song, Yongxi
    Gao, Peng
    Wang, Pengliang
    Wang, Chong
    Yu, Xueting
    Wei, Fengheng
    Guo, Jingyi
    Xu, Yingying
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (11) : 7054 - 7064
  • [37] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [38] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [39] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25)
  • [40] Therapy Standards in HER2-Positive Breast Cancer
    Gluz, Oleg
    Liedtke, Cornelia
    Marme, Frederik
    Thill, Marc
    BREAST CARE, 2016, 11 (02) : 148 - 150
12345